Rami Manochakian, Thoracic Medical Oncologist at Mayo Clinic and Vice President of the North American Neuroendocrine Tumor Society, shared a post on X:
“Hot Off The Press, Just published NEJM
In conjunction with the ESMO25 Presentation.
Results of SOHO-02 Phase 1/2 Trial of:
Sevabertinib in advanced HER2 mutant Non-Small Cell Lung Cancer.
ORR:
- 71% in treatment-naive
- 64% in pre-treated (No prior HER2 Tx)
- 38% in pre-treated (with prior HER2 Tx)”
Title: Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer
Authors: Xiuning Le, Tae Min Kim, Herbert H. Loong, Arsela Prelaj, Boon Cher Goh, Lin Li, Yong Fang, Shun Lu, Xiaorong Dong, Lin Wu, Yuki Shinno, Gennaro Daniele, Tsung-Ying Yang, Hye Ryun Kim, Gerrina Ruiter, Jun Zhao, Silvia Novello, Liyun Miao, Pasi A. Jänne, Koichi Goto, Dominik Rüttinger, Tine Descamps, Jan Christoph Brase, Weichao Bao, Rui Li, Nicoletta Brega, Paolo Grassi, Nicolas Girard, Daniel Shao-Weng Tan.
Read the Full Article in The New England Journal of Medicine.
More posts featuring Rami Manochakian on OncoDaily.